SR One Capital Management LP Makes New $3.15 Million Investment in KALA BIO, Inc. (NASDAQ:KALA)

SR One Capital Management LP acquired a new stake in KALA BIO, Inc. (NASDAQ:KALA) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund acquired 443,661 shares of the company’s stock, valued at approximately $3,146,000. KALA BIO makes up 1.0% of SR One Capital Management LP’s portfolio, making the stock its 9th biggest holding. SR One Capital Management LP owned 0.16% of KALA BIO at the end of the most recent reporting period.

KALA BIO Stock Down 0.2 %

Shares of NASDAQ KALA opened at $5.79 on Friday. The company has a debt-to-equity ratio of 1.97, a current ratio of 3.07 and a quick ratio of 3.07. The company has a 50-day moving average price of $6.25 and a 200-day moving average price of $6.66. The stock has a market capitalization of $16.30 million, a P/E ratio of -0.38 and a beta of -2.12. KALA BIO, Inc. has a 1 year low of $4.21 and a 1 year high of $10.97.

KALA BIO (NASDAQ:KALA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($3.16) EPS for the quarter, topping the consensus estimate of ($4.40) by $1.24. On average, equities research analysts forecast that KALA BIO, Inc. will post -11.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Oppenheimer reaffirmed an “outperform” rating and set a $15.00 price target on shares of KALA BIO in a research note on Monday, August 19th.

Insider Buying and Selling at KALA BIO

In other news, CEO Mark T. Iwicki sold 15,168 shares of the company’s stock in a transaction on Wednesday, June 26th. The shares were sold at an average price of $4.75, for a total value of $72,048.00. Following the completion of the sale, the chief executive officer now owns 263,755 shares in the company, valued at approximately $1,252,836.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In the last three months, insiders have sold 23,984 shares of company stock worth $113,924. Corporate insiders own 13.40% of the company’s stock.

KALA BIO Profile

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.